Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Clinical trial NCT03929029 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03929029
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-11
- Primary completion
- 2022-12-27
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.